All Oncology News

Tian Zhang, MD, discusses KEYNOTE-564, as well as the progress that immunotherapy has made in the treatment paradigm of patients with RCC.

Joseph A. Califano, MD, discusses how surgery factors into modern multidisciplinary care for patients with head and neck cancer.

Julie Graff, MD, comments on the state of immunotherapy in mCRPC and some ongoing research in the field.

Mothaffar Fahed Rimawi, MD, discusses the significance of precision medicine in HER2-positive breast cancer, as well as the possible role of immunotherapy for this specific population.

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended approval of ipilimumab for the treatment of pediatric patients aged 12 years and older with unresectable or metastatic melanoma.

The FDA has granted a priority review to a supplemental new drug application for the use of osimertinib as a first-line treatment for patients with non–small cell lung cancer whose tumors harbor EGFR mutations.

John Heinzerling, MD, discusses the impact of durvalumab and other developments in the treatment of patients with stage III non-small cell lung cancer.

Michael Bouvet, MD, highlights the evolving surgical options in the thyroid cancer field

The United Kingdom's National Institute for Health Care and Excellence has published new guidelines recommending ibrutinib as treatment for patients with relapsed/refractory mantle cell lymphoma.

Ferdinandos Skoulidis, MD, PhD, discusses potential treatment options for KRAS-mutated lung cancer and highlighted developments in biomarker research in other areas in the field.

Selinexor combined with weekly bortezomib and low-dose dexamethasone produced rapid and durable responses in a dose escalation/expansion trial of patients with relapsed/refractory multiple myeloma.

Pembrolizumab did not improve survival as a second-line treatment for PD-L1–positive patients with advanced gastric or gastroesophageal junction adenocarcinoma, according to findings from the phase III KEYNOTE-061 trial.

Assuntina G. Sacco, MD, discusses the importance of multidisciplinary care for patients with head and neck cancer.

Ten-year follow-up results from the StiL NHL1 study showed that frontline bendamustine (Treanda) plus rituximab (Rituxan) improved time-to-next-treatment compared with CHOP-R in patients with indolent lymphomas.

The combination of olaparib (Lynparza) and durvalumab (Imfinzi) demonstrated a disease control rate of 80% for pretreated patients with germline BRCA-mutated, HER2-negative metastatic breast cancer,

Adding ibrutinib to a standard frontline chemoimmunotherapy for chronic lymphocytic leukemia induced negative minimum residual disease status in bone marrow for 83% of patients.

Three-year safety results from the ALSYMPCA trial showed that treatment with radium-223 dichloride (Xofigo) for men with mCRPC and symptomatic bone metastases was associated with minimal nonhematologic AEs.

An analysis of racial disparities in prostate cancer treatment found that treatment underuse is rare, but when it does occur, it is almost exclusively in black men.

Michael Wang, MD, discusses the impact of acalabrutinib on patients with mantle cell lymphoma, ongoing progress in the field, and The University of Texas MD Anderson Cancer Center

The FDA has granted a priority review to a sBLA for use of the combination of nivolumab and ipilimumab as a frontline treatment for intermediate- and poor-risk patients with advanced RCC.

Investigators working in Malawi found an association between the combination of vincristine, bleomycin, and etoposide and improved quality of life, overall survival, and event-free survival in children with Kaposi sarcoma

Andrea Apolo, MD, discusses the management of immune-related adverse events in the treatment of bladder cancer.

Results from EMPOWER-CSCC 1 showed that cemiplimab (REGN2810) induced an overall response rate of 46.3% in patients with advanced cutaneous squamous cell carcinoma.

Andre Goy, MD, sheds light on some studies as well as future treatment options for patients with mantle cell lymphoma (MCL).

In results from the North Carolina Prostate Cancer Comparative Effectiveness and Survivorship Study, 52.6% said that preserving sexual function was “very important,” but only 43.4% were assigned to active surveillance.

Shubham Pant, MD, stresses the importance of clinical trials as an avenue to establish more novel treatment decisions in colorectal cancer.

Richard Furman, MD, discusses the current management of chronic lymphocytic leukemia and the future of combinations, including venetoclax and ibrutinib, for this patient population.

City of Hope announced that it has appointed Michael A. Caligiuri, M.D., in a new executive leadership role as president of City of Hope National Medical Center and physician-in-chief.

In top-line results from the phase III IMmotion151 trial, the combination of atezolizumab (Tecentriq) and bevacizumab (Avastin) was associated with a statistically significant reduction in the risk for death or progression in patients with PD-L1

Michael B. Atkins, MD, discusses hotly debated adjuvant treatment options for patients with melanoma, and the potential for neoadjuvant therapy.